Summary & Overview
HCPCS Level II E2103: Non‑adjunctive Continuous Glucose Monitor
Headline: HCPCS Level II code E2103: Non‑adjunctive Continuous Glucose Monitor Defined
Lead: HCPCS Level II code E2103 designates a non‑adjunctive, non‑implanted continuous glucose monitor or receiver used as durable medical equipment nationwide. The code reflects a growing shift toward continuous glucose monitoring technologies that provide stand‑alone glucose readings without reliance on traditional fingerstick meters.
What the code represents and why it matters: HCPCS Level II code E2103 identifies DME for continuous glucose monitoring that can be used independently for clinical decision making. As non‑adjunctive CGMs gain broader clinical acceptance, this code is central to coverage, procurement, and billing practices across the health care system.
Key payers covered: This publication addresses policy and billing considerations for Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
Overview of what readers will learn: Readers will find benchmarks for how E2103 is used relative to traditional blood glucose monitors, relevant policy and coverage considerations from major national payers, common billing modifiers and supply relationships, and the clinical context supporting non‑adjunctive CGM adoption. The report also highlights impacted supply codes and equipment replacement relationships.
Scope: National coverage and billing implications are summarized; state‑specific policy references are not included. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code E2103 describes a non‑adjunctive, non‑implanted continuous glucose monitor or receiver. This code falls under Durable Medical Equipment (DME) and denotes a continuous glucose monitoring device that can be used independently for glucose measurement rather than solely as an adjunct to a blood glucose meter.
Typical site of service for supplies and equipment billed with HCPCS Level II code E2103 is durable medical equipment suppliers (POS 54). Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with insulin-treated diabetes transitions from fingerstick glucose testing to a prescribed non-adjunctive continuous glucose monitor (CGM). The prescription for HCPCS Level II code E2103 is issued by the treating clinician based on documented need for real-time glucose monitoring to guide insulin dosing. The durable medical equipment supplier (Place of Service 54) receives the order, verifies beneficiary insurance coverage and any prior authorization requirements, and dispenses the non-implanted CGM or receiver. Typical workflow steps: clinician documents medical necessity and insulin treatment status, submits the order to the DME supplier, supplier confirms coding and modifier requirements (for example KX if the beneficiary is insulin-treated or KS if non‑insulin‑treated), bills the payer using HCPCS Level II code E2103, and coordinates ongoing supply allowances (for example A4239 when applicable) and continued coverage documentation (when CG applies).
Coding Specifications
-
Modifiers:
-
CG: Used for continued coverage when continued coverage criteria are met for non‑adjunctive CGM devices and supply allowance. -
KF: Used when CGM devices (E2103) and related supplies are classified by the U.S. Food and Drug Administration as Class III devices. -
KX: Used when the beneficiary is insulin‑treated (documents clinical criteria supporting coverage for the non‑adjunctive CGM). -
KS: Used when the beneficiary is non‑insulin‑treated (documents applicable coverage pathway for non‑insulin users, if permitted by payer policy). -
Associated provider taxonomies and specialties:
-
225100000X— Physical Therapist -
225X00000X— Rehabilitation Practitioner -
332B00000X— Durable Medical Equipment & Medical Supplies
Related Diagnoses
M54.5— Low back pain
Clinical relevance: Low back pain is listed among provided diagnoses; it does not directly indicate diabetes or need for glucose monitoring but may coexist in patients who require CGM for concurrent conditions or when chronic pain management involves medications that affect glucose.
M25.561— Pain in right knee
Clinical relevance: Knee pain is a musculoskeletal diagnosis that can coexist with diabetes; its presence may influence mobility and self‑management of glucose monitoring but is not a direct indication for E2103.
M79.7— Fibromyalgia
Clinical relevance: Fibromyalgia is a chronic pain syndrome that may coexist with diabetes; it can affect patient function and may be documented in the medical record alongside authorization for durable medical equipment but is not a specific indication for CGM.
R52— Pain, unspecified
Clinical relevance: Non‑specific pain diagnoses may be present in the patient's problem list; these are not specific indications for non‑adjunctive CGM but can be comorbid conditions documented in coverage reviews.
G89.29— Other chronic pain
Clinical relevance: Chronic pain diagnoses may be documented concurrently with diabetes care; like the other pain codes, they are generally comorbid and not primary clinical indications for HCPCS Level II code E2103.
Related Codes
-
E2100— Standard home blood glucose monitor (replaced by non‑adjunctive CGM whenE2103is billed). This code represents traditional glucometer equipment that is typically not billed concurrently when a non‑adjunctive CGM (E2103) is supplied. -
E2101— Standard home blood glucose monitor (replaced by non‑adjunctive CGM whenE2103is billed). This is an alternative legacy code for standard blood glucose monitors supplanted by CGM use. -
E0607— Standard home blood glucose monitor (replaced by non‑adjunctive CGM whenE2103is billed). Historically used for home glucose monitors; not generally billed alongsideE2103. -
A4233— Related supplies for standard BGMs (replaced whenE2103is billed). These supply HCPCS are for fingerstick testing supplies that are typically superseded by non‑adjunctive CGM supplies. -
A4234— Related supplies for standard BGMs (replaced whenE2103is billed). Similar supply group that may be inactivated when CGM supplies are provided. -
A4235— Related supplies for standard BGMs (replaced whenE2103is billed). Another fingerstick supply code commonly replaced clinically by CGM systems. -
A4236— Related supplies for standard BGMs (replaced whenE2103is billed). Represents alternate supply allowances for traditional glucose monitoring, typically not billed withE2103. -
A4239— Supply allowance for non‑adjunctive CGM devices. This code is used to bill consumable supplies associated withE2103and is commonly used together in the clinical workflow to capture ongoing supply needs.
Common usage notes: E2103 is the primary HCPCS Level II code for non‑implanted, non‑adjunctive CGM devices; the A42xx supply codes for standard blood glucose monitoring are generally replaced when E2103 and A4239 are used. Modifiers such as KX, KS, CG, and KF are appended per payer policy to indicate insulin treatment status, continued coverage, or FDA classification.
National Reimbursement Benchmarks
National mean allowed rates for HCPCS Level II code E2103 place Medicare at parity with the BUCA (average commercial) mean, both at $135.41, while Blue Cross Blue Shield reports the highest mean at $175.05 and Aetna the lowest at $99.12. UnitedHealthcare and Cigna Health report intermediate means of $142.89 and $119.31, respectively. The table and chart below present the full breakdown of payer means and percentiles.
Rate dispersion (P75 minus P25) varies notably across payers. Blue Cross Blue Shield shows the widest spread at $110.50 (211.00 - 100.50), indicating higher variability. Aetna and UnitedHealthcare show moderate dispersion at $35.60 and $39.92, respectively. Cigna Health is the tightest with no dispersion (P75 = P25 = $94.67). The table and chart below present the full breakdown.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.